COMMUNIQUÉS West-GlobeNewswire

-
Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA
03/06/2025 -
InspireMD Announces Appointment of Michael Lawless as Chief Financial Officer
03/06/2025 -
Merus N.V. Announces Proposed Public Offering of Common Shares
03/06/2025 -
Windtree Announces Plan for Cryptocurrency Treasury Policy
03/06/2025 -
Bicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
03/06/2025 -
HealthEquity Reports First Quarter Ended April 30, 2025 Financial Results
03/06/2025 -
Xenon to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
03/06/2025 -
Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
03/06/2025 -
Biofrontera Inc. Announces Patent for Propylene Glycol-Free Formula of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Now Listed in FDA Orange Book
03/06/2025 -
EssilorLuxottica: successful Euro 1 billion bond issuance
03/06/2025 -
EssilorLuxottica : Succès du placement d'une émission obligataire d’un montant d’1 milliard d'euros
03/06/2025 -
RESTEM to Present at the 2025 BIO International Convention
03/06/2025 -
Single infusion of CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) delivered lasting treatment-free remissions for at least five years in patients with relapsed or refractory multiple myeloma
03/06/2025 -
New analyses reinforce long-term benefit of DARZALEX® (daratumumab) subcutaneous-based quadruplet regimen for patients with newly diagnosed multiple myeloma
03/06/2025 -
Johnson & Johnson’s AKEEGA® (niraparib and abiraterone acetate dual-action tablet) is the first PARP inhibitor combo to show improved efficacy in patients with HRR-mutated mHSPC vs. current standard of care
03/06/2025 -
Legend Biotech Unveils Groundbreaking 5-Year Survival Data for CARVYKTI® in Multiple Myeloma at 2025 ASCO Annual Meeting
03/06/2025 -
Vital Wound Care Launches AI-Driven Wound App and Expands In-Home Services Across Greater Houston
03/06/2025 -
Epilepsy Foundation of America Awards $250,000 at 13th Annual Shark Tank Competition
03/06/2025 -
EssilorLuxottica: Result of the payment of dividends in shares and record of the corresponding capital increase
03/06/2025
Pages